SANOFI PASTEUR in phase III of DENGUE VACCINE

Vice President, Communications Sanofi Pasteur: Alain Bernal Vice President, Media and Scientific Communications: Pascal Barollier +33 4 3737 5038 Vice President, U.S. Communications: Len Lavenda +1 570 957 0717 Sanofi Pasteur S.A. Headquarters - 2, avenue Pont Pasteur - F-69367 Lyon cedex 07 - France Sanofi Pasteur Inc. – Discovery Drive – Swiftwater, PA 18370-0187 – USA – www.sanofipasteur.com

CHANGING THE LIVES OF MILLIONS

1 LEADING DENGUE VACCINE CANDIDATE

A GLOBAL PUBLIC HEALTH CHALLENGE

There is no specific treatment and vaccination is the only efficient means of fighting against dengue fever.

Sanofi Pasteur, a world leader in vaccines, has taken on the challenge of providing the first dengue vaccine for individuals living in endemic areas and developing countries as well as for those who plan to travel to those areas.

Dengue fever, a mosquito-borne disease caused by four types of dengue viruses, is a threat for almost half of the world’s population^(1).

Dengue fever occurs mostly in tropical and subtropical countries (2) and is spreading to new parts of the globe each year. Many factors contribute to the spreading of dengue fever, including urbanization and increased travel which facilitate the dissemination and the circulation of this disease.

Source: WHO, Global Health Observatory Map Gallery, available on: http://gamapserver.who.int/mapLibrary/Files/Maps/Global_DengueTransmission_ITHRiskMap.png

Key figures(1,3)…

An Aedes Aegypti mosquito which

spreads dengue

2

60 YEARS OF SCIENTIFIC ENDEAVOR

From early scientific discoveries ….

1944:

1944-45:

1956:

1970-1980: isolation and identification of the 1st serotype (in Hawaii, DEN1) and 2nd serotype (in N.Guinea, DEN2) by Sabin and Schelsinger(4). first monovalent dengue vaccine, a live attenuated vaccine (LAV) DEN1, developed by Sabin and Schelsinger(4). isolation and identification of the 3rd serotype (DEN3) and 4th serotype (DEN4) by W. Hammon(5). development of a tetravalent LAV DEN1, DEN2, DEN3, DEN4, by Pr Natth Bhamarapravati at the Mahidol University (Bangkok - Thailand). At this point, data from clinical investigations conducted in Thailand showed promise for a tetravalent dengue vaccine(6). Vice President, Communications Sanofi Pasteur: Alain Bernal Vice President, Media and Scientific Communications: Pascal Barollier +33 4 3737 5038 Vice President, U.S. Communications: Len Lavenda +1 570 957 0717 Sanofi Pasteur S.A. Headquarters - 2, avenue Pont Pasteur - F-69367 Lyon cedex 07 - France Sanofi Pasteur Inc. – Discovery Drive – Swiftwater, PA 18370-0187 – USA – www.sanofipasteur.com

• 2.5 billion people at risk in over 100 countries

• Estimated 220 million people infected annually

• 2 million, mostly children, develop dengue hemorrhagic fever, a severe form of the disease